ERBB2 and ovarian cancer: For HER2+ breast and ovarian cancers, trastuzumab-targeted bioconjugates were used, whereas the experiments with only polymer-stabilized Au@Pt and PtNPs were performed in HepG2 cells, commonly known to be a cancer cell line with a high degree of oxidative stress.